Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival

London (ots/PRNewswire) – - Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from a recently completed Phase III study with E7389 (generic name: eribulin mesylate, “eribulin”), discovered and developed by the Company, […]